Three type I diabetic patients nonresponsive to subcutaneous insulin were implanted with a subcutaneous peritoneal access device. In these patients, multiple subcutaneous injections had been unable to prevent recurrent hospital admissions for diabetic ketoacidosis. The patients were responsive to intravenous insulin but had limited accessible peripheral veins. Complications of thrombosis and/or septicemia from permanent central venous catheters prevented the long-term use of this route.
vent metabolic decompensation or recurrent hospital admissions for diabetic ketoacidosis. 1 The pathogenesis of this syndrome is complex and may involve both insulin degradation and/or sequestration at the subcutaneous injection site.
1 -2 Alternative insulin delivery sites in these patients have been the intravenous and intramuscular routes, but recurrent thrombosis, septicemia, and muscle fibrosis have limited their usefulness. During the past 5 yr, we have been investigating the feasibility of intraperitoneal insulin delivery to control hyperglycemia both in diabetic man and animals. 4 In parallel with these studies, we have been developing a subcutaneously implanted peritoneal access device through which insulin can be safely injected into the peritoneum. 5 Recently, three patients have been referred to us because of repeated failures to prevent diabetic ketoacidosis in spite of large doses of subcutaneous insulin injections. Each of these patients was incapacitated by his or her diabetes, being unable to attend school or work. After establishing that these patients responded to intraperitoneal insulin delivery (via a temporary peritoneal catheter), each patient was implanted with a subcutaneous peritoneal access device. Our results suggest that this device may provide an alternative insulin delivery site in these difficult to manage, subcutaneously nonresponsive diabetic patients.
METHODS
Patient population. The clinical description of the three type I diabetic patients referred to us by their physicians is shown in Table 1 . Each physician was a specialist in the care of diabetic patients and was unsuccessful in maintaining these patients in metabolic control. Two of the patients (nos. #1 and #3) had tried the addition of apoprotinin (Trasylol) to their insulin, without success. 1 All patients had limited peripheral access veins and one had been implanted with two subclavian catheters and three intramuscular catheters, all of which had thrombosed or become infected (patient no. 2). All patients were unable to work or attend school because of the multiple hospitalizations required to treat metabolic decompensation. During the previous 6 mo, an The subcutaneous peritoneal access. The subcutaneous peritoneal access shown in Figure 1 has three components: (1) an injection port, (2) an 0.5 ml dead space beneath the injection port, and (3) a silicone rubber peritoneal catheter. The injection port is machined from polypropylene, into which is fitted a 1.8-cm-diameter trilayer silicone rubber septum (Hamilton Co., Reno, Nevada). Beneath the septum is a nonexpandable dead space of approximately V2 ml. From this dead space exits a 53-cm silicone rubber catheter, of which 36 cm is coiled beneath the polypropylene shield and 17 cm is external to the shield. The inside volume of this catheter is an additional 1 /2-ml dead space. Eight centimeters distal to the shield, the catheter is encircled by a 1 /2-cm-diameter silicone rubber cuff to permit suturing of the catheter to the linea alba. Nine centimeters distal to the silicone rubber cuff, the peritoneal catheter terminates in a one-way low pressure valve (Ames catheter, Dow Coming, Ann Arbor, Michigan) which prevents obstruction of the catheter by omentum. The entire subcutaneously implanted peritoneal access is coated with medical grade biocompatible silicone rubber (Dow Corning) The implantation site. The subcutaneous peritoneal access device is implanted above or below the umbilicus through a 5-cm midline incision. The terminal 9 cm of the catheter is placed within the peritoneal space via a 2-mm incision in the linea alba and parietal peritoneum. The silicone rubber cuff is then sutured to the linea alba as the parietal peritoneum is closed. The subcutaneous peritoneal access port is placed lateral (right or left) to the midline incision via a subcutaneous tunnel approximately V2 cm below the skin surface. The entire operation is performed under local anesthesia and requires approximately 45 min. Prior to the operation and for an additional 48-h period, the patient is administered broad spectrum antibiotics.
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RESULTS
Subcutaneous peritoneal access devices have been implanted in three type I diabetic patients, providing a cumulative experience of 9 mo. No infections, obstructions, or insulin precipitations have been experienced with the implanted devices. Prior to injection of insulin into the implanted subcutaneous peritoneal access port, a radiocontrast study with fluoroscopy was performed to ensure that the device was intact with the appropriate anatomical drainage into the peritoneal cavity (Figure 2 ). These studies have demonstrated that the peritoneal portion of the catheter is mobile within the peritoneal cavity, thereby not subjecting the same area of peritoneum to continuous insulin exposure. In one patient requiring peritoneoscopy following 2 mo of implantation for right upper quadrant abdominal pain (unrelated to the subcutaneous peritoneal access device), the silicone rubber catheter tip was observed to be free-floating in the peritoneal cavity, without tissue reaction or fatty deposits. Administration of insulin into the subcutaneous peritoneal access device is easily performed by the patient by injecting the insulin transcutaneously with a 2772-gauge insulin syringe needle through the septum of the subcutaneously palpable port. Confirmation of the correct position of the syringe needle is made by a "specific feel" that the septum and access port give to the injection. Furthermore, when the tip of the needle is in the correct location, the insulin flows without resistance or local sensation into the access device. We use U100 insulin in a ratio of 1:1 of regular to protamine zinc (Eli Lilly and Co., Indianapolis, Indiana). To this mixture is added 25 meq/L of sterile sodium bicarbonate (Abbott Laboratories, Chicago, Illinois) to prevent isoelectric precipitation. 8 Since there is a nonexpandable dead space in the subcutaneous peritoneal access device of 1 ml, once this device is filled with insulin, injection of any volume into the access port results in the same volume of insulin exiting from the device's catheter tip into the peritoneal space.
DISCUSSION
This study demonstrates the successful use of a subcutaneously implanted peritoneal access device for patients who respond poorly to subcutaneous insulin injections. At least 1 wk prior to implantation, a temporary peritoneal catheter was inserted into the abdomen of each patient to document responsiveness to intraperitoneally administered insulin. 9 Following implantation of the device, we recommend that the patients inject insulin at times of meal ingestion every 8 h into the peritoneal access to maintain good metabolic control. The injection of a 1:1 ratio of regular to protamine zinc insulin provides an acute rise in plasma insulin concentration with the associated meals (breakfast, supper, and midnight snack), plus a background dose of insulin throughout the postprandial 8-h period (Figure 3) . Although protamine zinc insulin administered subcutaneously may last up to 36 h, when given intraperitoneally, the biologic effectiveness begins to wane at 8 h. When regular and protamine zinc insulin is premixed for up to 2 mo, a loosely dissociated complex occurs which minimally effects the biologic activity of the regular insulin (personal communication, Dr. Richard L Jackson, Eli Lilly and Company, Indianapolis, Indiana).
The subcutaneous peritoneal access device overcomes the principal drawback of external intraperitoneal insulin delivery, i.e., the risk of peritonitis. By totally implanting the device below the skin, no external bacteria readily gain entrance to the peritoneum. Although injection through the skin into the access port might theoretically introduce bacteria, no infections have been observed in spite of an average of three injections per day throughout 9 mo of experience. The other potential route of bacterial entrance into the peritoneum is via the injection of contaminated insulin. To prevent contaminated insulin from reaching the peritoneum through the device and its peritoneal catheter, a 1 ml dead space is included in its design to self-sterilize insulin. 10 To date all patients, their families, and their physicians have been pleased with the subcutaneous peritoneal access devices. Throughout the 9 mo of experience, only one of the patients has required re-hospitalization for metabolic control and adjustment of her peritoneal insulin dosage (from two injections per 24 h to three injections per 24 h). Since the access port's septum is only 1.8 cm in diameter, the patients must be careful not to repeatedly inject into the septum through the same location in the skin, which might lead to tissue breakdown. To prevent this, the diabetic patient is taught to pull new skin over the access port so that the tenderness does not develop from repeated injections. If the skin does become erythematous, the patient can then use an alternative delivery route (intravenous) for several days to permit skin recovery. Additional experience will be required to define which patient populations will benefit from implantation of a subcutaneous peritoneal access device, and what biologic lifetime may be experienced with the system.
